10x Genomics (TXG) Current Deferred Revenue (2018 - 2026)

10x Genomics has disclosed Current Deferred Revenue across 9 years of filings, most recently posting $33.3 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue fell 0.65% year-over-year to $33.3 million; the TTM figure through Jun 2026 stood at $33.3 million (down 0.65% YoY), while the FY2025 annual figure was $34.4 million, up 3.71% from the prior year.
• Current Deferred Revenue came in at $33.3 million for Q2 2026 at 10x Genomics, down from $34.5 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $34.5 million in Q1 2026 to a low of $7.9 million in Q1 2022.
• Average Current Deferred Revenue over 5 years is $23.4 million, with a median of $26.0 million recorded in 2024.
• Year-over-year, Current Deferred Revenue soared 100.0% in 2024 and dropped 0.65% in 2026.
• Over 5 years, Current Deferred Revenue stood at $11.0 million in 2022, then jumped by 99.09% to $22.0 million in 2023, then jumped by 51.02% to $33.2 million in 2024, then rose by 3.71% to $34.4 million in 2025, then decreased by 3.21% to $33.3 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $33.3 million in Q2 2026, $34.5 million in Q1 2026, and $34.4 million in Q4 2025.